CAM
CMPX icon

Cormorant Asset Management’s Compass Therapeutics CMPX Stock Holding History

Cormorant Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,030,823
Closed -$2.03M – 47
2024
Q2 		$2.03M Sell
2,030,823
-3,529,477
-63% -$5.15M 0.12% 47
2024
Q1 		$11M Buy
+5,560,300
New +$9.61M 0.48% 42

Other funds holding CMPX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Cormorant Asset Management's CMPX Position: Q3 2024 in Review

Cormorant Asset Management sold out of Compass Therapeutics (CMPX) in Q3 2024, closing a stake of 2,030,823 shares — an estimated $2.03M sold.

Cormorant Asset Management first reported a position in CMPX in Q1 2024 and held it in 2 quarters. The position peaked at $11M in Q1 2024. 79 funds tracked by Wall St. Rank hold CMPX as of Q3 2024.

  • Cormorant Asset Management reported no remaining Compass Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 2,030,823 Compass Therapeutics shares in Q3 2024, an estimated $2.03M.
  • Cormorant Asset Management first reported a position in Compass Therapeutics in Q1 2024 and held it in 2 quarters.
  • Cormorant Asset Management's Compass Therapeutics position peaked at $11M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2024.

Based on Cormorant Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.